close

Enter

Log in using OpenID

Hodgkin’s Lymphoma Treatment Market

embed
Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma.
Hodgkin’s Lymphoma Treatment Market – Global
Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2019 – 2027
Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two
types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be
characterized into two categories – classic and nodular lymphocyte predominant. Some of the
signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden weight loss, and
swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with
the combination of radiotherapy.
Request Sample Copy of Research Report @ http://bit.ly/30SYZhP
Global Hodgkin’s Lymphoma Treatment Market Drivers
Approvals of the drugs by regulatory bodies for the treatment of Hodgkin’s lymphoma is
expected to drive the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics,
Inc. received the Health Canada approval for its supplemental New Drug Submission that
expands the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin,
vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV
Hodgkin lymphoma (HL). Adcetris is indicated for the treatment of adult patients with
previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with
doxorubicin, vinblastine, and dacarbazine.
Furthermore, key players are constantly trying to expand the indications of their already
approved drug. For instance, in March 2017, Merck & Co. Inc. received an approval by U.S.
Food & Drug Administration (FDA) of the drug, Keytruda for the treatment of classical
Hodgkin’s lymphoma. It is approved on the basis of response durability and tumor response
rate and is supposed to be administered intravenously into patients. It was originally approved
in 2014. Such frequent approvals of drugs by regulatory bodies are expected to impact
positively on the global Hodgkin’s lymphoma treatment market growth.
Report includes chapters which deeply display the following deliverable about industry :
• Hodgkin’s Lymphoma Treatment Market Research Objective and Assumption
• Hodgkin’s Lymphoma Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Hodgkin’s Lymphoma Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Hodgkin’s Lymphoma Treatment Market, By Regions
• Hodgkin’s Lymphoma Treatment Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Hodgkin’s Lymphoma Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Hodgkin’s Lymphoma Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Hodgkin’s Lymphoma Treatment Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Hodgkin’s Lymphoma Treatment Market Regional Analysis
North America is expected to hold a dominant position in the global Hodgkin’s lymphoma
market over the forecast period. Frequent research and development activities done by the
government and other organizations is expected to drive the North America Hodgkin’s
lymphoma treatment market growth. For instance, in December 2016, Ohio State University
Comprehensive Cancer Center and National Cancer Institute (NCI) commenced a U.S. FDA
clinical trial of Ibrutinib in combination with Nivolumab, in the patients suffering from classical
Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cell
growth by blocking the enzymes responsible for growth and Nivolumab may block cancer cells
by targeting different cells. Currently, it’s in the second phase of clinical trials. The study
involves 17 participants and is estimated to be completed by 2020.
Furthermore, various outside organizations are involved in research and development activities
for development and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma treatment
drug in the U.S.
Request For Customization of Research Report @ http://bit.ly/2Keuc9h
For instance, in September 2017, Chinese PLA General Hospital, a Chinese government
organization, commenced its clinical trial of Decitabine in combination with SHR – 1210. It is
being used for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody,
while Decitabine is an investigational drug, which is capable of boosting antigen expression.
The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in the
second phase of clinical trials.
Global Hodgkin’s Lymphoma Treatment Market Restraints
Side effects related with drugs used for the treatment of Hodgkin’s lymphoma is expected to
adversely affect adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma
treatment market growth. For instance, according to American Cancer Society, drugs used for
treating Hodgkin’s lymphoma such as doxorubicin and bleomycin can damage heart and lungs
respectively. Hence, such side effects of drugs can hinder the global Hodgkin’s lymphoma
treatment market growth.
Global Hodgkin’s Lymphoma Treatment Market Key Players
Some of the major players operating in the global Hodgkin’s lymphoma treatment market
include Emcure Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals
Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences
Inc., Jansenn Research and Development LLC, and Merck & Co., Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge390   documents Email
Document
Category
Health and Medicine
Views
7
File Size
123 KB
Tags
Hodgkin’s Lymphoma Treatment Market, treatment
1/--pages
Report inappropriate content